Going beyond IHC to, for the first time, directly quantify the functional protein landscape of tumors in FFPE samples.
PharmaShots delves into Sapient’s mission to transform multi-omics research through innovation & world-class partnerships.
Extending molecular insights beyond DNA and RNA to realize new value in existing FFPE tissue biobanks.
A look at how AI-driven, multi-omics platforms are advancing the discovery and development of precision medicines.
Unlocking functional biology, new biomarker insights, and responder profiles from archived trial samples.
Using TAA profiling to identify differentially expressed, disease-modifying, tractable targets on the cell surface.
Delivering quantitative, reproducible protein measures for rapid proof-of-mechanism & target engagement insights.
Using multi-omics to characterize changes in inflammatory markers observed following GLP-1 therapy.
Transforming archival tissue into a discovery-ready resource to move from target discovery to functional validation, in weeks.
We explore known & novel associations of creatinine using Sapient’s DynamiQ™ Insights Engine. See what we find.
Enabling measure of 10K+ proteins in FFPE tissue & tumors and multi-omic molecular mapping of tumor biology.
Unlocking functional tumor biology from FFPE tissue – quantitatively, reproducibly, and at scale.
